Breaking News

EUROAPI Invests €50M to Meet Growing Demand for Prostaglandins

State-of-the-art manufacturing equipment to double overall prostaglandin capacity of the Budapest site by 2027.

EUROAPI, a company focused on reinventing active ingredient solutions, announced a €50 million investment for the installation of a new state-of-the-art production plant at its Budapest site. The project will be focused on the debottlenecking of the current capacity and the construction of new multi-purpose manufacturing equipment that will more than double the overall prostaglandin capacity of the Budapest site by 2027 in two phases: 2023-2025 (approximately 2/3 of the total investment) and 202...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters